5.44
price down icon8.57%   -0.51
pre-market  プレマーケット:  5.50   0.06   +1.10%
loading
前日終値:
$5.95
開ける:
$5.87
24時間の取引高:
169.13K
Relative Volume:
0.54
時価総額:
$120.10M
収益:
$66.59M
当期純損益:
$-104.93M
株価収益率:
-1.099
EPS:
-4.95
ネットキャッシュフロー:
$-96.48M
1週間 パフォーマンス:
-3.37%
1か月 パフォーマンス:
+15.01%
6か月 パフォーマンス:
-51.69%
1年 パフォーマンス:
-64.14%
1日の値動き範囲:
Value
$5.44
$5.87
1週間の範囲:
Value
$5.44
$6.23
52週間の値動き範囲:
Value
$4.09
$17.23

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Name
名前
Enanta Pharmaceuticals Inc
Name
セクター
Healthcare (1150)
Name
電話
617 607 0800
Name
住所
4 KINGSBURY AVENUE, WATERTOWN, MA
Name
職員
131
Name
Twitter
@EnantaPharma
Name
次回の収益日
2025-02-10
Name
最新のSEC提出書
Name
ENTA's Discussions on Twitter

ENTA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ENTA
Enanta Pharmaceuticals Inc
5.44 120.10M 66.59M -104.93M -96.48M -4.95
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
500.19 127.64B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
603.58 65.95B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
656.65 37.92B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
273.55 32.98B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
254.16 26.92B 3.81B -644.79M -669.77M -6.24

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-08-09 ダウングレード JP Morgan Neutral → Underweight
2023-08-08 ダウングレード Jefferies Buy → Hold
2022-12-09 開始されました H.C. Wainwright Buy
2022-07-06 アップグレード Evercore ISI In-line → Outperform
2022-06-01 アップグレード Evercore ISI Underperform → In-line
2021-10-07 開始されました Jefferies Buy
2021-09-09 開始されました SVB Leerink Mkt Perform
2021-01-29 アップグレード JP Morgan Underweight → Neutral
2020-11-24 開始されました Evercore ISI Underperform
2020-08-28 再開されました ROTH Capital Buy
2020-08-26 開始されました Piper Sandler Overweight
2020-07-27 アップグレード JMP Securities Mkt Perform → Mkt Outperform
2020-03-17 アップグレード Robert W. Baird Neutral → Outperform
2019-11-22 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2019-09-26 ダウングレード JP Morgan Neutral → Underweight
2019-05-24 開始されました Wolfe Research Outperform
2019-04-23 アップグレード Berenberg Hold → Buy
2018-12-13 開始されました Berenberg Hold
2018-06-06 開始されました ROTH Capital Buy
2018-02-08 ダウングレード JP Morgan Overweight → Neutral
2018-01-02 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2017-11-21 繰り返されました RBC Capital Mkts Outperform
2017-09-15 開始されました RBC Capital Mkts Outperform
2017-07-11 アップグレード JMP Securities Mkt Perform → Mkt Outperform
2016-04-28 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2016-02-09 繰り返されました Barclays Underweight
2015-10-23 ダウングレード Barclays Equal Weight → Underweight
2015-10-23 アップグレード JMP Securities Mkt Perform → Mkt Outperform
すべてを表示

Enanta Pharmaceuticals Inc (ENTA) 最新ニュース

pulisher
May 05, 2025

Enanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to Analysts - Yahoo Finance

May 05, 2025
pulisher
Apr 27, 2025

JMP Securities maintains Enanta stock with $21 target - MSN

Apr 27, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 23, 2025

(ENTA) Investment Report - news.stocktradersdaily.com

Apr 23, 2025
pulisher
Apr 08, 2025

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation At Escmid Global 2025 - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025 - Business Wire

Apr 08, 2025
pulisher
Apr 08, 2025

Breakthrough RSV Treatment Achieves Double Success in Latest Clinical Trial - Stock Titan

Apr 08, 2025
pulisher
Apr 07, 2025

(ENTA) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Apr 07, 2025
pulisher
Apr 05, 2025

Enanta stock hits 52-week low at $4.71 amid market challenges - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

Enanta stock hits 52-week low at $4.71 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Mar 31, 2025

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Not Doing Enough For Some Investors As Its Shares Slump 27% - simplywall.st

Mar 31, 2025
pulisher
Mar 27, 2025

Enanta Pharmaceuticals at H.C. Wainwright: Strategic Shift to Immunology By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 27, 2025

(ENTA) Proactive Strategies - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 25, 2025

Drug Co. Wants Fed. Circ. To Undo Pfizer COVID Patent Win - Law360

Mar 25, 2025
pulisher
Mar 17, 2025

Enanta Reveals Latest Autoimmune Drug Progress: Key Presentation March 27 - StockTitan

Mar 17, 2025
pulisher
Mar 17, 2025

How To Trade (ENTA) - Stock Traders Daily

Mar 17, 2025
pulisher
Mar 15, 2025

Enanta Pharmaceuticals Reports Q1 EPS Loss of $1.05, Beating Est - GuruFocus.com

Mar 15, 2025
pulisher
Mar 12, 2025

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13 - Business Wire

Mar 12, 2025
pulisher
Mar 06, 2025

Insider Buying: Jay Luly Acquires 45,000 Shares of Enanta Pharma - GuruFocus.com

Mar 06, 2025
pulisher
Mar 01, 2025

Investor Network: Enanta Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 01, 2025
pulisher
Feb 28, 2025

Enanta Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 28, 2025

Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below 200 Day Moving AverageHere's What Happened - MarketBeat

Feb 28, 2025
pulisher
Feb 24, 2025

(ENTA) Trading Advice - Stock Traders Daily

Feb 24, 2025
pulisher
Feb 20, 2025

Market Watch Highlights: Enanta Pharmaceuticals Inc (ENTA) Ends on an Upturn Note at 8.30 - The Dwinnex

Feb 20, 2025
pulisher
Feb 19, 2025

Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded at StockNews.com - MarketBeat

Feb 19, 2025
pulisher
Feb 19, 2025

Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded to “Hold” at StockNews.com - Defense World

Feb 19, 2025
pulisher
Feb 17, 2025

HC Wainwright Has Pessimistic Outlook of ENTA Q2 Earnings - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

Enanta Pharmaceuticals' SWOT analysis: RSV and immunology drive stock outlook - MSN

Feb 17, 2025
pulisher
Feb 17, 2025

Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target at $17.25 - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Purchases $256,050.00 in Stock - MarketBeat

Feb 17, 2025
pulisher
Feb 16, 2025

Enanta Pharmaceuticals CEO Luly Jay R. buys $256,050 in common stock - MSN

Feb 16, 2025
pulisher
Feb 16, 2025

Enanta Pharmaceuticals (NASDAQ:ENTA) Cut to "Sell" at StockNews.com - MarketBeat

Feb 16, 2025
pulisher
Feb 15, 2025

With Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their Returns - Yahoo Finance

Feb 15, 2025
pulisher
Feb 15, 2025

President of Enanta Pharmaceuticals Picks Up 5.9% More Stock - Yahoo Finance

Feb 15, 2025
pulisher
Feb 15, 2025

Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade - MSN

Feb 15, 2025
pulisher
Feb 15, 2025

Enanta Pharmaceuticals (NASDAQ:ENTA) Receives "Market Outperform" Rating from JMP Securities - MarketBeat

Feb 15, 2025
pulisher
Feb 14, 2025

Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Shares Bounce 55% But Its Business Still Trails The Industry - Simply Wall St

Feb 14, 2025
pulisher
Feb 14, 2025

Enanta Pharmaceuticals’ (ENTA) “Buy” Rating Reiterated at HC Wainwright - Defense World

Feb 14, 2025
pulisher
Feb 14, 2025

HC Wainwright maintains $18 target on Enanta shares, affirms Buy - MSN

Feb 14, 2025
pulisher
Feb 13, 2025

Enanta Pharmaceuticals (NASDAQ:ENTA) Releases Quarterly Earnings Results - MarketBeat

Feb 13, 2025
pulisher
Feb 12, 2025

Enanta Pharmaceuticals Advances in Virology and Immunology - TipRanks

Feb 12, 2025
pulisher
Feb 12, 2025

Enanta Pharmaceuticals CEO Luly Jay R. buys $256,050 in common stock By Investing.com - Investing.com South Africa

Feb 12, 2025

Enanta Pharmaceuticals Inc (ENTA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$72.58
price up icon 0.39%
$21.55
price up icon 0.33%
$33.00
price up icon 0.33%
$28.02
price up icon 0.43%
$101.10
price down icon 3.66%
biotechnology ONC
$254.16
price down icon 0.63%
大文字化:     |  ボリューム (24 時間):